Next 10 |
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, pleas...
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“I...
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” ...
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IB...
Lexaria Bioscience (NASDAQ:LEXX,CSE:LXX) concluded its expanded research program for DehydraTECH-enabled remdesivir and ebastine, showing effective results in inhibiting the COVID-19 SARS-CoV-2 virus . Lexaria Bioscience CEO Chris Bunka discussed the technology ’s poten...
(TheNewswire) - Two of the four planned studies progressing to examine DehydraTECH™ with antivirals targeting SARS-CoV-2 / COVID-19 Kelowna, British Columbia - TheNewswire - March 16, 2021 – Lexaria Bioscien...
(TheNewswire) - Lexaria recently expanded its hypertension R&D program evaluating effectiveness of DehydraTECH-processed CBD to three human clinical studies and two animal studies Kelowna, British Columbia – TheNewswir...
(TheNewswire) Kelowna, British Columbia – TheNewswire - February 16, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”),...
(TheNewswire) - Hypertension program evaluating effectiveness of DehydraTECH-processed CBD now consists of three human clinical studies and two animal studies Kelowna, British Columbia – TheNewswire - February 11, 2021...
(TheNewswire) Kelowna, British Columbia - TheNewswire - February 1, 2021 – Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (C NSX :LXX. CN ) (the “Company” or “Lexaria”), a global ...
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Company Name:
LXRP Stock Symbol:
OTCMKTS Market:
Lexaria Bioscience Corp. Website:
NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Hypertension: The Silent Killer Making Loud Noise for Investors.” To hear the AudioPressRelease, pleas...
NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“I...
NEW YORK, Aug. 06, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Cardiovascular Disease Drug Market Offers Compelling Potential for First Movers, Innovators in the Space.” ...